Nature Medicine

Article	Citations
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	3079
Post-acute COVID-19 syndrome	2973
Extrapulmonary manifestations of COVID-19	2191
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections	2182
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19	2009
A global survey of potential acceptance of a COVID-19 vaccine	1810
An inflammatory cytokine signature predicts COVID-19 severity and survival	1779
Attributes and predictors of long COVID	1581
A serological assay to detect SARS-CoV-2 seroconversion in humans	1521
Age-dependent effects in the transmission and control of COVID-19 epidemics	1291
A single-cell atlas of the peripheral immune response in patients with severe COVID-19	1228
Real-time tracking of self-reported symptoms to predict potential COVID-19	1099
Long-term cardiovascular outcomes of COVID-19	1057
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	825
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	822
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	768
A dynamic COVID-19 immune signature includes associations with poor prognosis	718
AI in health and medicine	709
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19	687
Digital technologies in the public-health response to COVID-19	684
COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	664
Seasonal coronavirus protective immunity is short-lasting	587
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	586
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	536
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	535

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma	509
SARS-CoV-2 infection of the oral cavity and saliva	508
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	486
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	484
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	483
Immune determinants of COVID-19 disease presentation and severity	481
Targeting metastatic cancer	472
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong	472
Determinants of COVID-19 disease severity in patients with cancer	466
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	460
Long COVID after breakthrough SARS-CoV-2 infection	456
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	455
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda	452
Single-cell multi-omics analysis of the immune response in COVID-19	446
Looking beyond COVID-19 vaccine phase 3 trials	444
Long COVID in a prospective cohort of home-isolated patients	438
Symptoms and risk factors for long COVID in non-hospitalized adults	433
Understanding COVID-19 vaccine hesitancy	430
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	429
Infection of bat and human intestinal organoids by SARS-CoV-2	427
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	425
Human postprandial responses to food and potential for precision nutrition	421
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	418
Biomarkers for neurodegenerative diseases	416
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein	414
Intratumoral heterogeneity in cancer progression and response to immunotherapy	397
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors	394
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	387
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	385
Human–computer collaboration for skin cancer recognition	384
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	382
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	372
Toward personalized treatment approaches for non-small-cell lung cancer	368
Deep learning in histopathology: the path to the clinic	366
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	366
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	363
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes	363
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	362
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	360
A deep learning system for differential diagnosis of skin diseases	359
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19	355
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension	350
Partial recovery of visual function in a blind patient after optogenetic therapy	346
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	345
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	343
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	337
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	337
Brown adipose tissue is associated with cardiometabolic health	337
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	337
Disease and healthcare burden of COVID-19 in the United States	336

Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	336
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	331
Modeling COVID-19 scenarios for the United States	327
Large language models in medicine	326
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	324
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	323
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	323
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China	321
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	319
Sixteen novel lineages of SARS-CoV-2 in South Africa	314
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis	314
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	312
Wearable sensor data and self-reported symptoms for COVID-19 detection	310
Federated learning for predicting clinical outcomes in patients with COVID-19	310
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection	308
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	307
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	299
SARS-CoV-2 variants of concern are emerging in India	297
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle	297
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors	296
Cellular senescence and senolytics: the path to the clinic	296
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial	295
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	295
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial	290
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	285
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	283
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries	282
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	281
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	280
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	269
A single-cell landscape of high-grade serous ovarian cancer	268
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	268
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial	267
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist	267
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling	266
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters	265
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	263
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease	262
Acute and postacute sequelae associated with SARS-CoV-2 reinfection	258
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	256
Targeting the HIF2–VEGF axis in renal cell carcinoma	255
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	251
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	250
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade	248
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial	248
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster	246
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	243
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection	242
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands	242
Unexplained post-acute infection syndromes	242
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	241
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension	241
Microglial activation and tau propagate jointly across Braak stages	238
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	238
A stochastic agent-based model of the SARS-CoV-2 epidemic in France	238
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	237
Long-term neurologic outcomes of COVID-19	236
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	234
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures	233
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	229
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	226
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	224
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	220
Multimodal biomedical AI	219
Vaccine development for emerging infectious diseases	217
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	215
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	214
Closed-loop neuromodulation in an individual with treatment-resistant depression	214
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	213
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	213
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	213
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	212
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial	212
A guide to immunotherapy for COVID-19	211
The distribution of cellular turnover in the human body	209
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring	209
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	207
A roadmap to increase diversity in genomic studies	206
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma	205
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial	204

Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	203
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	201
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	198
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	197
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies	197
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer	196
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	196
Articular cartilage regeneration by activated skeletal stem cells	195
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	195
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models	195
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	194
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	194
Crowding and the shape of COVID-19 epidemics	192
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma	191
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	191
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial	190
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study	189
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	188
Increased global integration in the brain after psilocybin therapy for depression	185
Using a real-world network to model localized COVID-19 control strategies	184
Modeling shield immunity to reduce COVID-19 epidemic spread	183
The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk	182
Modeling transmission of SARS-CoV-2 Omicron in China	181
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease	180
Global maps of travel time to healthcare facilities	180
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology	178
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma	176
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2	176
Delayed production of neutralizing antibodies correlates with fatal COVID-19	175
Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis	173
Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial	173
Reporting guidelines for human microbiome research: the STORMS checklist	173
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial	172
COVID-19 dynamics after a national immunization program in Israel	172
Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1	171
Predicting conversion to wet age-related macular degeneration using deep learning	171
Reconstruction of the human blood–brain barrier in vitro reveals a pathogenic mechanism of APOE4 in pericytes	171
SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland	170
Targeting the gut and tumor microbiota in cancer	168
A correlate of protection for SARS-CoV-2 vaccines is urgently needed	168
Prediction of mortality from 12-lead electrocardiogram voltage data using a deep neural network	167
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial	166
Impaired meningeal lymphatic drainage in patients with idiopathic Parkinson’s disease	166
Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes	166
COVID-19 and resilience of healthcare systems in ten countries	165
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer	165
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers	164
Misinformation: susceptibility, spread, and interventions to immunize the public	164
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial	163
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial	163
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors	162
Developing specific reporting guidelines for diagnostic accuracy studies assessing AI interventions: The STARD-AI Steering Group	161
The landscape of mRNA nanomedicine	161
Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes	159
Wearable-device-measured physical activity and future health risk	159
An epidemic of uncertainty: rumors, conspiracy theories and vaccine hesitancy	159
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis	159
COVID-19 in Africa: the spread and response	159
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma	159
Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial	158
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021	158
Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium	157
Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy	157
Colibactin DNA-damage signature indicates mutational impact in colorectal cancer	152
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis	152
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge	152
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis	150
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial	150
Antibody-mediated inhibition of GDF15–GFRAL activity reverses cancer cachexia in mice	149
An algorithmic approach to reducing unexplained pain disparities in underserved populations	147
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor	146
How COVID-19 shaped mental health: from infection to pandemic effects	144
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines	143
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial	142
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma	142
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis	142
The next generation of evidence-based medicine	140
Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19	140
AI in medicine must be explainable	140
Myocardial infarction accelerates breast cancer via innate immune reprogramming	139
Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI	139
Redefining critical illness	138
Distinction of lymphoid and myeloid clonal hematopoiesis	137
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma	136
Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma	135
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)	135
Humoral signatures of protective and pathological SARS-CoV-2 infection in children	133
Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases	133
Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19	132
Cartography of opportunistic pathogens and antibiotic resistance genes in a tertiary hospital environment	132
Modeling human adaptive immune responses with tonsil organoids	132
Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19	131
Single-cell atlas of colonic CD8+ T cells in ulcerative colitis	131
Insulin dose optimization using an automated artificial intelligence-based decision support system in youths with type 1 diabetes	131
Delivering precision oncology to patients with cancer	130